Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Fluorescent Dye Reveals Biochemical Conversations Between Cartilage and Bone in Early Osteoarthritis

By HospiMedica International staff writers
Posted on 08 Oct 2024

Osteoarthritis (OA) is a painful condition where the cartilage in a joint deteriorates, causing bone-on-bone contact. More...

This articular cartilage also calcifies, turning into bone. The progressive condition is prevalent in individuals over 60, as well as those with certain metabolic disorders or who experience repetitive joint stress. Although there is no cure, early interventions may help slow further damage. However, detecting OA in its early stages, before the onset of pain, has been challenging. Now, researchers have discovered that a fluorescent dye might allow them to "listen" to biochemical interactions between cartilage and bone during the earliest stages of OA—even before pain begins. This unexpected discovery, made through research on mice, could pave the way for new treatments.

Researchers at Sidney Kimmel Medical College of Thomas Jefferson University (Philadelphia, PA, USA) investigated whether articular cartilage becomes calcified in the early stages of OA. They used a mouse model in which the right knee displays symptoms resembling those of human OA. The team injected a fluorescent red dye called alizarin complexone, which binds to calcium-containing crystals, into both knees. Surprisingly, they found no fluorescence on the surface of the articular cartilage, where they had expected to see early calcification. Instead, the dye stained the tidemark region, a boundary between the articular cartilage and the layer of calcified cartilage on the bone. The researchers also observed that the osteoarthritic mice had more alizarin dye in the calcified cartilage and subchondral bone compared to the controls. This increased dye diffusion suggests that the knee joint in early OA is more permeable than in normal joints.

When injected, the dye first enters the synovial fluid, which lubricates the joints. In additional experiments, the team found that the dye moved throughout the joint via three expected pathways. However, they also discovered a new pathway, through the tidemark, into the blood vessels in the outer bone layer, known as the periosteum. The fluorescence signal was stronger in the periosteum and subchondral bone of OA-affected joints compared to controls. These findings, published in FASEB BioAdvances, reveal that alizarin complexone can detect diffusion, or biochemical communication, between the articular cartilage, calcified cartilage, and subchondral bone. This diffusion is heightened in the early stages of OA. With this new tool, researchers can further explore OA progression, potentially leading to the development of novel treatments.


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.